SCHEMBL20239142

SCHEMBL20239142

COc1nc(C#N)cc(Oc2ccc(CS(=O)(=O)N(C)C(=O)O)cc2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
MAPK8 P45983 1/20 0.35
MAPK9 P45984 1/20 0.35
P2RX3 P56373 1/20 0.34
PLA2G10 O15496 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
SIRT2 Q8IXJ6 1/20 0.34
TAS2R14 Q9NYV8 1/20 0.34
CYP1A2 P05177 2/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2C19 P33261 2/20 0.33
GAA P10253 1/20 0.33
POLB P06746 1/20 0.33
KMT2A Q03164 1/20 0.33
SNCA P37840 1/20 0.33
TSHR P16473 1/20 0.33
TXNRD1 Q16881 1/20 0.33
CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16738672 0.88 PDE2A (0.36) ALDH1A1HPGDMAPK8MAPK9SMN1; SMN2
SCHEMBL20252435 0.88 ALDH1A1 (0.33) ALDH1A1MAPTHPGDMAPK8MAPK9
SCHEMBL20239274 0.86 SMN1; SMN2 (0.41) ALDH1A1SMN1; SMN2GAAPOLBKMT2A
SCHEMBL20239134 0.86 PTPN1 (0.33) ALDH1A1MAPK8MAPK9PLA2G10SMN1; SMN2
SCHEMBL20239283 0.86 SMN1; SMN2 (0.34) ALDH1A1MAPTHPGDMAPK8MAPK9
SCHEMBL20239238 0.85 KDM4E (0.35) ALDH1A1MAPTSMN1; SMN2KMT2A
SCHEMBL20239308 0.84 SMN1; SMN2 (0.34) ALDH1A1PLA2G10SMN1; SMN2CYP1A2CYP2C19
SCHEMBL20239258 0.83 PDE4B (0.34) ALDH1A1MAPTHPGDMAPK8MAPK9
SCHEMBL16738668 0.75 SMN1; SMN2 (0.43) ALDH1A1MAPTHPGDSMN1; SMN2CYP1A2
SCHEMBL16738676 0.75 GPR119 (0.36) ALDH1A1MAPK8MAPK9SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT ALDH1A1 1430/4885MAPT 2739/4885HPGD 2550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.